Michael T. Andriole

President, Chief Executive Officer, and Director

Therapeutic Areas

Drug	Indication	Phase
alnodesertib (ART0380)	Platinum-resistant ovarian cancer (and other solid tumors)	Phase 2
ART6043	gBRCA-mutated HER2-negative breast cancer (and other solid tumors)	Phase 1/2